{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:47:38Z","timestamp":1788058058002,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The high prevalence of long-term persisting symptoms after COVID-19 (coronavirus disease 2019), termed long COVID or post-COVID-19 condition, even among those with mild initial disease, may have a large public health impact. Apart from avoiding infection, there is no proven prevention or treatment for long COVID. We will perform a randomized placebo-controlled clinical trial to assess whether treatment with the novel antiviral, nirmatrelvir and ritonavir (Paxlovid\u00ae) for acute COVID-19 can prevent the development of long COVID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a randomized double-blinded placebo-controlled trial that aims to recruit 2000 nonpregnant persons aged 18 to 64\u00a0years with acute COVID-19 with positive PCR and\/or antigen test and symptom duration of not more than 5\u00a0days. Participants will be randomized 1:1 to a 5-day course of Paxlovid (two tablets 150-mg nirmatrelvir and one tablet 100-mg ritonavir twice daily) or a 5-day course of placebo (similar number of tablets of equal appearance). The primary endpoint will be persistent symptoms compatible with long COVID, assessed as the prevalence of a dichotomous variable corresponding to the presence (1) or absence (0) of one or more of the following symptoms: (i) fatigue, (ii) dyspnea, and (iii) cognitive symptoms (memory and\/or concentration problems). The primary outcome will be evaluated at 3-month follow-up and then re-evaluated at 6, 12, and 24\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>As more than 750 million people with confirmed COVID-19 have survived globally, the potential burden of long COVID on societies is formidable. If a simple 5-day oral treatment course with nirmatrelvir\/ritonavir is shown to prevent long COVID, it would be a highly attractive intervention at an individual level and a mitigation of its public health consequences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT05852873. Registered on May 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09226-6","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:15:24Z","timestamp":1762427724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomized trial of nirmatrelvir\/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-4297","authenticated-orcid":false,"given":"Bj\u00f8rn","family":"Blomberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai Norevik","family":"Myklebust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oddvar","family":"Oppegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Jane","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arild","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Emblem","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Sandvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuva B\u00f8rresdatter","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke Devold","family":"Valderhaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szodoray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Wilhelmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Eivind","family":"Kirsebom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte","family":"Glambek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oddvar","family":"Kaarb\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolv Terje","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Langeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"9226_CR1","unstructured":"WHO. World Health Organization COVID-19 Dashboard. 2024. Available from: https:\/\/data.who.int\/dashboards\/covid19. cited 2025 Feb 25"},{"key":"9226_CR2","doi-asserted-by":"crossref","unstructured":"Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607\u201313. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34163090","DOI":"10.1038\/s41591-021-01433-3"},{"key":"9226_CR3","doi-asserted-by":"crossref","unstructured":"Blomberg B, Cox RJ, Langeland N. Long-COVID: a growing problem in need of intervention. Cell Rep Med. 2022;3:100552. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35474749","DOI":"10.1016\/j.xcrm.2022.100552"},{"key":"9226_CR4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","volume":"226","author":"C Chen","year":"2022","unstructured":"Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-Coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593\u2013607.","journal-title":"J Infect Dis"},{"key":"9226_CR5","doi-asserted-by":"crossref","unstructured":"Fjelltveit EB, Blomberg B, Kuwelker K, Zhou F, Onyango TB, Brokstad KA, et al. Symptom burden and immune dynamics 6 to 18 months following mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): a case-control study. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2022;76:e60\u201370. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35959897","DOI":"10.1093\/cid\/ciac655"},{"key":"9226_CR6","doi-asserted-by":"crossref","unstructured":"Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Condition WHOCCDWG on P-C-19. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102\u20137. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34951953","DOI":"10.1016\/S1473-3099(21)00703-9"},{"key":"9226_CR7","doi-asserted-by":"crossref","unstructured":"Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023? Pol Arch Intern Med. 2023;133. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36626183","DOI":"10.20452\/pamw.16402"},{"key":"9226_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.38804","volume":"5","author":"RH Perlis","year":"2022","unstructured":"Perlis RH, Santillana M, Ognyanova K, Safarpour A, Trujillo KL, Simonson MD, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5:e2238804.","journal-title":"JAMA Netw Open"},{"key":"9226_CR9","doi-asserted-by":"crossref","unstructured":"Ertesv\u00e5g NU, Iversen A, Blomberg B, \u00d6zg\u00fcm\u00fc\u015f T, Rijal P, Fjelltveit EB, et al. Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. eBioMedicine. 2023;92:104599. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37149931","DOI":"10.1016\/j.ebiom.2023.104599"},{"key":"9226_CR10","doi-asserted-by":"crossref","unstructured":"Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023; Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37605079","DOI":"10.1038\/s41591-023-02521-2"},{"key":"9226_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192214739","volume":"19","author":"TB Nielsen","year":"2022","unstructured":"Nielsen TB, Leth S, Pedersen M, Harbo HD, Nielsen CV, Laursen CH, et al. Mental fatigue, activities of daily living, sick leave and functional status among patients with long COVID: a cross-sectional study. Int J Environ Res Public Health. 2022;19:14739.","journal-title":"Int J Environ Res Public Health"},{"key":"9226_CR12","doi-asserted-by":"crossref","unstructured":"Ledford H. Long-COVID treatments: why the world is still waiting. Nature. 2022;608:258\u201360. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35945375","DOI":"10.1038\/d41586-022-02140-w"},{"key":"9226_CR13","doi-asserted-by":"crossref","unstructured":"Wang S, Li Y, Yue Y, Yuan C, Kang JH, Chavarro JE, et al. Adherence to Healthy Lifestyle Prior to Infection and Risk of Post-COVID-19 Condition. JAMA Intern Med. 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36745445","DOI":"10.1001\/jamainternmed.2022.6555"},{"key":"9226_CR14","doi-asserted-by":"crossref","unstructured":"Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461\u20137. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35614233","DOI":"10.1038\/s41591-022-01840-0"},{"key":"9226_CR15","doi-asserted-by":"crossref","unstructured":"Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474\u201384. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34320281","DOI":"10.1056\/NEJMoa2109072"},{"key":"9226_CR16","doi-asserted-by":"crossref","unstructured":"Boglione L, Meli G, Poletti F, Rostagno R, Moglia R, Cantone M, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114:865\u201371. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34850210","DOI":"10.1093\/qjmed\/hcab297"},{"key":"9226_CR17","doi-asserted-by":"crossref","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397\u2013408. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35172054","DOI":"10.1056\/NEJMoa2118542"},{"key":"9226_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2204919","volume":"387","author":"R Arbel","year":"2022","unstructured":"Arbel R, Sagy YW, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge. N Engl J Med. 2022;387:790\u20138.","journal-title":"N Engl J Med"},{"key":"9226_CR19","doi-asserted-by":"crossref","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813\u201326. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32445440","DOI":"10.1056\/NEJMoa2007764"},{"key":"9226_CR20","doi-asserted-by":"crossref","unstructured":"Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ. 2010;340:c2073. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20442226","DOI":"10.1136\/bmj.c2073"},{"key":"9226_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa2309002","volume":"391","author":"J Hammond","year":"2024","unstructured":"Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, et al. Oral nirmatrelvir-ritonavir as postexposure prophylaxis for covid-19. N Engl J Med. 2024;391:224\u201334.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09226-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09226-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09226-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:15:29Z","timestamp":1762427729000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09226-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9226"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09226-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by the Regional Committees for Medical and Health Research Ethics with the case number REC-SE-578741. Written informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The informed consent form is attached.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"477"}}